Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2009 3
2010 5
2011 2
2012 4
2013 11
2014 11
2015 12
2016 9
2017 15
2018 12
2019 11
2020 14
2021 15
2022 8
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28385782

125 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Noble RA, et al. Haematologica. 2017 Jul;102(7):1247-1257. doi: 10.3324/haematol.2016.163030. Epub 2017 Apr 6. Haematologica. 2017. PMID: 28385782 Free PMC article.
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow CJ. Polański R, et al. Clin Cancer Res. 2014 Feb 15;20(4):926-937. doi: 10.1158/1078-0432.CCR-13-2270. Epub 2013 Nov 25. Clin Cancer Res. 2014. PMID: 24277449 Free PMC article.
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A. Quanz M, et al. Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16. Mol Cancer Ther. 2018. PMID: 30115664
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC. Dalton KM, et al. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118. Proc Natl Acad Sci U S A. 2021. PMID: 33762304 Free PMC article.
125 results